Revolution's Daraxonrasib Extends Pancreatic Survival
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines advanced daraxonrasib into a clinical trial, where patient Leanna Stokes experienced markedly longer survival than typical metastatic pancreatic cancer outcomes.
- Kevan Shokat proved KRAS can be drugged, spurring first‑generation inhibitors that helped only roughly 1% of pancreatic cancer patients and quickly met resistance.
- KRAS inhibitors are now being evaluated by dozens of companies in clinical studies, expanding the therapeutic pipeline for KRAS‑mutant cancers.
Why it matters: Patients with KRAS‑mutant pancreatic cancer gain longer survival; Revolution Medicines, whose daraxonrasib is in trial, will serve the roughly 1% of pancreatic cancer patients previously eligible for KRAS drugs, driving a surge in oncology investment.
Ask SkimNews
